Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.chom.2021.01.014 http://scihub22266oqcxt.onion/10.1016/j.chom.2021.01.014 33535027!7839837!33535027     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Host+Microbe 2021 ; 29 (3): 477-488.e4 Nephropedia Template TP {{tp|p=33535027|t=2021. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization |pdf=|usr=}}{{33535027}} gab.com Text Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization JO: Cell Host Microbe http://www.kidney.de/pget.php?&tw=1&pmid=33535027 #FOAvip Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19 vaccines and have received emergency use authorization as therapeutics. However, viral escape mutants could compromise efficacy. To define immune-selected mutations in the S protein, we exposed a VSV-eGFP-SARS-CoV-2-S chimeric virus, in which the VSV glycoprotein is replaced with the S protein, to 19 neutralizing monoclonal antibodies (mAbs) against the receptor-binding domain (RBD) and generated 50 different escape mutants. Each mAb had a unique resistance profile, although many shared residues within an epitope of the RBD. Some variants (e.g., S477N) were resistant to neutralization by multiple mAbs, whereas others (e.g., E484K) escaped neutralization by convalescent sera. Additionally, sequential selection identified mutants that escape neutralization by antibody cocktails. Comparing these antibody-mediated mutations with sequence variation in circulating SARS-CoV-2 revealed substitutions that may attenuate neutralizing immune responses in some humans and thus warrant further investigation. Twit Text FOAVip Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization ????Cell Host Microbe http://www.kidney.de/pget.php?&tw=1&pmid=33535027 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33535027 #FOAvip English Wikipedia <ref>{{Cite pmid|33535027}}</ref> Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization #MMPMID33535027 Liu Z; VanBlargan LA; Bloyet LM; Rothlauf PW; Chen RE; Stumpf S; Zhao H; Errico JM; Theel ES; Liebeskind MJ; Alford B; Buchser WJ; Ellebedy AH; Fremont DH; Diamond MS; Whelan SPJ Cell Host Microbe 2021[Mar]; 29 (3): 477-488.e4 PMID33535027show ga Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19 vaccines and have received emergency use authorization as therapeutics. However, viral escape mutants could compromise efficacy. To define immune-selected mutations in the S protein, we exposed a VSV-eGFP-SARS-CoV-2-S chimeric virus, in which the VSV glycoprotein is replaced with the S protein, to 19 neutralizing monoclonal antibodies (mAbs) against the receptor-binding domain (RBD) and generated 50 different escape mutants. Each mAb had a unique resistance profile, although many shared residues within an epitope of the RBD. Some variants (e.g., S477N) were resistant to neutralization by multiple mAbs, whereas others (e.g., E484K) escaped neutralization by convalescent sera. Additionally, sequential selection identified mutants that escape neutralization by antibody cocktails. Comparing these antibody-mediated mutations with sequence variation in circulating SARS-CoV-2 revealed substitutions that may attenuate neutralizing immune responses in some humans and thus warrant further investigation. |*Mutation[MESH] |Amino Acid Substitution[MESH] |Angiotensin-Converting Enzyme 2/genetics[MESH] |Animals[MESH] |Antibodies, Monoclonal/*blood/immunology[MESH] |Antibodies, Neutralizing/immunology/pharmacology[MESH] |Antibodies, Viral/*blood/immunology[MESH] |COVID-19 Vaccines/immunology[MESH] |COVID-19/virology[MESH] |Chlorocebus aethiops[MESH] |Female[MESH] |Humans[MESH] |Mice[MESH] |Mice, Inbred BALB C[MESH] |Models, Molecular[MESH] |Neutralization Tests/*methods[MESH] |Protein Binding[MESH] |Receptors, Virus/metabolism[MESH] |SARS-CoV-2/*genetics/immunology[MESH] |Spike Glycoprotein, Coronavirus/*genetics/immunology[MESH]Identification of SARS-CoV-2 spike mutations that attenuate monoclonal(epmc).pdf DeepDyve Pubget Overpricing